NT5E and cancer: A bispecific antibody to CD73 and EpCAM not only reduced the CD73 activity of these cancer-derived EVs, but also inhibited the effects of CD73 on reducing T-cell proliferation and rescued the anti-tumor properties of T-cells[126].